Showing results (161-170 of 270) with videos related to

Sort By:
Pageof 27
The Breast Journal|December 15, 2019
Use of scalp cooling device to prevent alopecia for early breast cancer patients receiving chemotherapy: A prospective studyTommaso Giarratano, Simona Frezzini, Monica Zanocco, et al.
Oncotarget|April 19, 2017
GD2 expression in breast cancerGiulia Orsi, Monica Barbolini, Guido Ficarra, et al.
JCO Oncology Practice|April 7, 2021
Non-Small-Cell Lung Cancer: Real-World Cost Consequence AnalysisAlessandra Buja, Giulia Pasello, Giuseppe De Luca, et al.
BMJ Oncology|June 24, 2025
Reduced duration adjuvant trastuzumab in the treatment of patients with HER2-positive breast cancer: a meta-analysis of randomised controlled non-inferiority trials including IPD dataHelena M Earl, Louise Hiller, Janet A Dunn, et al.
Breast Cancer Research : BCR|June 23, 2018
Immune characterization of breast cancer metastases: prognostic implicationsMaria Vittoria Dieci, Vassilena Tsvetkova, Enrico Orvieto, et al.
European Journal of Cancer (Oxford, England : 1990)|July 12, 2023
Platinum-based chemotherapy and PARP inhibitors for patients with a germline BRCA pathogenic variant and advanced breast cancer (LATER-BC): retrospective multicentric analysis of post-progression treatmentsCarmine Valenza, Dario Trapani, Sara Gandini, et al.
Medical Oncology (Northwood, London, England)|April 2, 2017
SAFE trial: an ongoing randomized clinical study to assess the role of cardiotoxicity prevention in breast cancer patients treated with anthracyclines with or without trastuzumabIcro Meattini, Giuseppe Curigliano, Francesca Terziani, et al.
European Journal of Cancer (Oxford, England : 1990)|June 21, 2021
Trastuzumab-lapatinib as neoadjuvant therapy for HER2-positive early breast cancer: Survival analyses of the CHER-Lob trialValentina Guarneri, Maria V Dieci, Gaia Griguolo, et al.
Journal of the National Cancer Institute|September 7, 2023
Metastatic site patterns by intrinsic subtype and HER2DX in early HER2-positive breast cancerMaria Vittoria Dieci, PierFranco Conte, Giancarlo Bisagni, et al.
European Journal of Cancer (Oxford, England : 1990)|December 23, 2025
PIK3CA mutations and first-line outcomes in endocrine-resistant HR+/HER2- metastatic breast cancer: A multicentric real-world studyMaria Vittoria Dieci, Grazia Vernaci, Chiara Colangelo, et al.
Pageof 27